3月24日,联邦制药发布公告:与诺和诺德签订独家许可协议,将一款长效GLP-1R/GIPR/GCGR三靶点激动剂(UBT251)海外权益授予诺和诺德。根据协议,联邦制药将获得2亿美元预付款、最高18亿美元的潜在里程碑付款,以及授权地区的分层销售提成。2023年来,中国创新药license-out的频率越来越高,国产GLP-1更是达成多笔巨额对外授权,阿斯利康、默沙东接连抛出橄榄枝。联邦制药此前并未...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.